Significant association of antiphospholipid antibodies and TNF-alpha: Marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications

Cytokine

Volumn 55, Issue 2, 2011, Pages 301-306

  Becarevic, Mirjana ^a,b   Seferovic, Jelena ^b   Ignjatovic, Svetlana ^b,c   Singh, Sandra ^b   Majkic Singh, Nada ^b,c  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Antiphospholipid antibodies; Atherosclerosis; Diabetes mellitus type II; TNF alpha

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN E; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LIPOCORTIN 5 ANTIBODY; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PHOSPHOLIPID ANTIBODY; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL OBESITY; ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MICROCIRCULATION; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR DISEASES;

EID: 80955179024     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.05.001     Document Type: Article

References (27)

1. American Diabetes association, Diagnosis and classification of diabetes mellitus, Diabetes Care 33 (2010) S62-S69.
2. Čolak E., Majkić-Singh N. The effect of hyperglycemia and oxidative stress on the development and progress of vascular complications in type 2 diabetes. J Med Biochem 2009, 28:63-144.
3. Popa C., Netea M.G., van Riel P.L.C.M., van der Meer J.W.M., Stalenhoef A.F.H. The role of TNH-alpha in chronic inflammatory conditions intermediary metabolism and cardiovascular risk. J Lipid Res 2007, 48:751-762.
4. Pickup J C. Inflammation and activated innate immunity in the pathogenesis of type II diabetes mellitus, Diabetes Care 27 (2004) 813-823.
5. Pruzanski W., Vadas P., Browing J. Secretory pancreatic group II phospholipase A2: role in physiologic and inflammatory processes. J Lipid Mediat 1993, 8:161-167.
6. Nomura S., Kanazawa S., Fukuhara S. Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with type II diabetes mellitus. J Diabetes and its Complications 2003, 17:153-159.
7. Palinski W., Witztum J.L. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med 2000, 247:371-380.
8. Colwell J.A. Treatment for the procoagulant state in type II diabetes. Endokrinol Metab Clin North Am 2001, 30:1011-1030.
9. Lefvert A K. Heterogeneity of autoantibodies against cardiolipin and oxidatively modified LDLs revealed by human monoclonal antibodies. J Intern Med 247 (2000) 385-390.
10. Bećarević M., Andrejević S., Bonači-Nikolić B., Obradović I., Miljić P., Majkić-Singh N. Anti-oxLDL antibodies - marker for arterial thromboses in antiphospholipid syndrome?. Clin Lab 2005, 51:279-283.
11. Bećarević M., Singh S., Majkić-Singh N., Oxidized L.D.L. Anti-oxidized LDL and anti-annexin A5 antibodies in primary antiphospholipid syndrome. Clin Lab 2008, 54:97-101.
12. Bećarević M., Andrejević S., Miljić P., Bonači-Nikolić B., Majkić-Singh N. Serum lipids and anti-oxidized LDL antibodies in primary antiphospholipid syndrome. Clin Exp Rheumatol 2007, 25:361-366.
13. Varaala O. Autoantibodies to modified LDLs and other phospholipid-protein complexes as markers of cardiovascular diseases. J Intern Med 2000, 247:381-384.
14. Rand J.H., Wu X.X., Quin A.S., Chen P.P., McCrae K.R., Bovill E.G., et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers. Am J Pathol 2003, 163:1193-1200.
15. American Heart association: Heart and Stroke facts. Dallas: American Heart Association, 1992.
16. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20 (1997) 1183-1197.
17. Ettinger W.H., Varna V.K., Sorci-Thomas M., Parks J.S., Sigmon R.C., Smith T.K., et al. Cytokine decreases apolipoprotein accumulation in medium from HepG2 cells. Arterioscler Thromb 1994, 14:8-13.
18. Katsuki A., Sumida Y., Murashima S., et al. Serum levels of TNF-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metabol 1998, 83:859-862.
19. Ziccardi P., Nappo F., Giuglino G., et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002, 105:804-809.
20. Ciarla M V, Bocciarelli A, Di Gregorio S, et al., Autoantibodies and endothelial dysfunction in well-controlled, uncomplicated insulin-dependent diabetes mellitus patients, Atherosclerosis (2001) 241-246.
21. Palomo J.G., Mujica V.E., Alarcon M.L., Pereira J.G., Vasquez M. Prevalence of antiphospholipid antibodies is not different in Chilean diabetic and normal individuals. J Diabetes and its complications 2005, 19:133-137.
22. Galtier-Dereure F, Biron C, Vies M, Bourgeois V, Schued J, Bringer J, Vascular complications of diabetes mellitus. What role for phospholipid - binding antibodies? Lupus 7 (1998) 469-74.
23. Gargiulo P., Goldberg J., Romani B., Schiaffini R., Ciampalini P., Faulk W.P., et al. Qualitative and quantitative studies of autoantibodies to phospholipids in diabetes mellitus. Clin Exp Immunol 1999, 118:30-34.
24. Cuadrado M.J., Lopez-Pedrera C., Khamashta M.A., Camps M.T., Tinahones F., Torres A., et al. Thrombosis in primary antiphsopholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997, 40:834-841.
25. Vega-Ostertag M., Casper K., Swerlick R., Ferrara D., Harris E.N., Pierangelli S.S. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphsopholipid antibodies. Arthritis Rheum 2005, 52:1545-1554.
26. Lopes-Pedrera C., Buendia P., Cuadrado M.J., Siendones E., Aguirre M.A., Barbrroja N., et al. Antiphospholipid antibodies from patients with antiphospholipid syndrome induce monocyte tissue expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Athritis Rheum 2006, 54:301-311.
27. Doring Y., Hurst J., Lorenz M., et al. Human antiphospholipid antibodies induce TNFα in monocytes via Toll-like receptor 8. Immunobiology 2010, 215:230-241.